• BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
FinanceTime
  • August 19th, 2026

FinanceTimeFinancetime

  • BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
Bottles of prescription painkiller OxyContin pills, made by Purdue Pharma LP sit on a counter at a local pharmacy in Provo, Utah, U.S., April 25, 2017. George Frey
Bottles of prescription painkiller OxyContin pills, made by Purdue Pharma LP sit on a counter at a local pharmacy in Provo, Utah, U.S., April 25, 2017. George Frey
Home
Business
Healthcare & Pharmaceuticals

Purdue Pharma, Sacklers reach $7.4 bln national opioid settlement

January 23rd, 2025 | 17:06 PM BUSINESS Healthcare & Pharmaceuticals 3

Facebook Twitter Google+ LinkedIn Pinterest

Worth reading...

Platelets can be chilled and stored for weeks, not days, study shows
Lundbeck sees no slowdown in key drugs despite cautious 2026 outlook, CEO says
Ebola cases in Congo exceed 5,000, government data shows
Cyclosporiasis cases in US climb to 15,716, CDC says
By Dietrich Knauth

Purdue Pharma and its Sackler family owners have reached a new $7.4 billion settlement to resolve thousands of lawsuits alleging that the pain medication OxyContin caused a widespread opioid addiction crisis in the U.S., several state attorneys general said Thursday.

The settlement was announced nearly seven months after the U.S. Supreme Court upended the company's previous attempt to resolve the lawsuits in a bankruptcy settlement that would have granted the Sacklers sweeping civil immunity from opioid lawsuits in exchange for a payment of up to $6 billion.

The Supreme Court ruled that the Sacklers, who did not file for bankruptcy themselves, were not entitled to legal protections meant to give bankrupt debtors a "fresh start."

Under the new settlement, the Sacklers will pay $6.5 billion, with another $900 million coming from Purdue, without fully shutting off lawsuits from states, local governments, or individual victims of the opioid crisis. Those who do not wish to join the settlement are free to pursue lawsuits against the Sacklers, who have said they would vigorously defend themselves in court.

Connecticut attorney General William Tong said that the settlement would help provide closure to victims of the opioid crisis.

"It's not just about the money," Tong said. "There is not enough money in the world to make it right."

The latest settlement is meant to address a drug addiction crisis that has led to over 700,000 opioid overdose deaths in the United States over the past two decades.

Purdue said Thursday that it was working to incorporate the settlement into a new bankruptcy plan.

"We are extremely pleased that a new agreement has been reached that will deliver billions of dollars to compensate victims, abate the opioid crisis, and deliver treatment and overdose rescue medicines that will save lives," Purdue said in a statement.

Purdue is one of many drug manufacturers, distributors, pharmacy operators and others who have collectively in recent years agreed to pay about $50 billion to resolve lawsuits and investigations by states and local governments accusing them of helping fuel a deadly opioid addiction epidemic in the U.S.

Purdue filed for bankruptcy in 2019 in the face of thousands of lawsuits accusing it and members of the Sackler family of fueling the epidemic through deceptive marketing of its highly addictive pain medicine.

The company pleaded guilty to misbranding and fraud charges related to its marketing of OxyContin in 2007 and 2020. Members of the Sackler family have denied wrongdoing but expressed "regret" over OxyContin's role in the opioid crisis.

  • Topic
  • PURDUE PHARMA
  • BANKRUPTCY/OPIOIDS (UPDATE 1)
Facebook Twitter Google+ LinkedIn Pinterest
Previous article Platelets can be chilled and stored for weeks, not days, study shows

Related Posts

Healthcare & Pharmaceuticals
August 19th, 2026

Platelets can be chilled and stored for weeks, not days, study shows

Healthcare & Pharmaceuticals
August 19th, 2026

Lundbeck sees no slowdown in key drugs despite cautious 2026 outlook, CE...

Healthcare & Pharmaceuticals
August 19th, 2026

Ebola cases in Congo exceed 5,000, government data shows

Healthcare & Pharmaceuticals
August 18th, 2026

Cyclosporiasis cases in US climb to 15,716, CDC says

Healthcare & Pharmaceuticals
August 18th, 2026

Amylyx drug cuts low blood sugar episodes in bariatric surgery patients ...

Healthcare & Pharmaceuticals
August 18th, 2026

WHO says Congo Ebola outbreak can still be brought under control within ...

The Wire
Aug 19th 2 h ago
Litigation

Greater regulatory scrutiny no bar to mining mergers, bosse...

Aug 19th 2 h ago
Energy

Turkey is ready to search for oil and gas in Syria, Turkish...

Aug 19th 2 h ago
Technology

Nebius plans $4.5 billion convertible debt sale to fund dat...

Aug 19th 2 h ago
Baseball

Now healthy, Blue Jays' Max Scherzer takes aim at Rays

Aug 19th 2 h ago
Retail & Consumer

Off-price retailer TJX raises annual profit forecasts

TRENDING ON FINANCETIME
Aug 19th, 2026 Business

European corporate outlook keeps improving as recovery goes beyond energy profits

Aug 19th, 2026 Baseball

With Jo Adell in question, Guardians chase series win vs. Giants

Aug 19th, 2026 Technology

Analog Devices' quarterly forecast tops estimates on AI-fueled chip demand

Aug 19th, 2026 India

Global shocks, IPO wave could temper India's earnings-led market revival, Abakkus Investment says

Aug 19th, 2026 Africa

Egypt to widen cash subsidy scheme to cover more essential foods

Markets-Sectors
HEALTHCARE +1.60%

  • BUSINESS
  • MARKETS
  • WORLD
  • POLITICS
  • TECH
  • COMMENTARY
  • BREAKINGVIEWS
  • MONEY
  • LIFE
  • SECTORS
  • Back to top
FinanceTime
FinanceTime

World Business & Financial News, Breaking US & International News

Additional Services
  • Privacy-Policy
  • Terms and Conditions
© Financetime.org 2026. All rights reserved. Hosted by LeadsDeposit.com
Produced by C-iT